Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
It will keep creeping and we will see £2 within a week. Much better to do that than the boom and bust volatility of the past.
You're invested in THE most promising treatment out there for a virus that is causing a global pandemic.
News coverage is now going around the world which will bring more institutional investment in, particularly from US biotech investors.
Just sit back and enjoy it rising a few % each week for the next couple of months.
Going global. Glowing review in four minute long TV slot on CNBC Canada. Video below.
https://twitter.com/NatashaFatah/status/1349379813115645954
L2 means nothing that early. Most orders don't appear on the book till a couple of minutes before 8. Still likely to be fairly flat as holders weren't waiting for this to buy more.
What could push it on is the media coverage as the man on the street realises he can buy shares in that company he just saw on BBC news.
Seen lots of shares do this as a seller gets towards the end of offloading their holding. You start seeing bigger amounts of the ask as they advertise what they've got left. Could be the guys from the other day finishing up.
The trick is catching it just as they finish and buyers take control.
First of all it was always $3000 USD, which is £2200.
SNG001 is a 14 day course, and then there's the fact it's patented in the nebulised form.
I like to go on worst case figures when investing so that any surprises are to the upside. If each treatment costs only £1000 and they stick to only making 100k of them a month that's £100m per month minimum.
£1.2bn per year, before any licensing agreements, for a company with a £300m market cap.
The wider application of this for Asthma and COPD means this will get bought by a large pharmaceutical company, in the £3-4bn range.
Got an order in at 136.
There have been no mass sell offs even with the delays so I think there are too many people waiting to buy any dip. Were pretty much back to where we were a week ago but with dosing news and potentially other interesting updates ready to drop at any minute.
Can all the de-rampers put in a better effort please, I would like to average up.
We've got a drug that works at an earlier stage than the ones announced last night, can potentially help with long COVID and is broad spectrum so has wide application and will likely deal with any future COVID variants.
I would really like to add more but so far your bashing is having no impact so maybe there won't be a dip for me to buy on and I'll just have to FOMO buy.
At least 14% of the shares in SNG are held by two institutions and these are just the ones over 3% that we know about. They haven't sold anything for months and in fact one of them has been buying more. Then the directors hold a few % between them and they haven't sold anything either.
Anyone who has done the slightest bit of research is holding strong as the big move is just around the corner.
This has always been the case. A vaccine helps your body to be prepared for a virus WHEN you catch it. It doesn't prevent you catching it at all.
PCR tests in particular are very sensitive so can pick up even small amounts of the virus. Your vaccinated body will stop the virus duplicating as much and harming you, so a less sensitive test like a LFT probably wouldn't have picked him up as infected.
Could this be the reason we've been delayed a few days... to register the trial on ILAP.
"We have developed an ambitious new pathway to accelerate patient access to innovative medicines. The Innovative Licensing and Access Pathway (ILAP), is now open for business."
Lord Bethell, Minister for Innovation says:
"We are absolutely determined to make sure UK patients can access the latest cutting-edge medicines as quickly as possible to help everybody live longer, healthier and happier lives."
https://www.gov.uk/government/news/the-mhra-innovative-licensing-and-access-pathway-is-open-for-business